P3 Health Partners

Persistent Regulatory Risk And Consolidation Will Constrain Future Margins

AnalystLowTarget

Not Invested

Community Contributor

Published

31 Aug 25

AnalystLowTarget's Fair Value

US$8.00

22.0% overvalued

31 Aug

US$9.76

-50.2%

18.4%

-50.2%

18.4%

You can edit this narrative until Aug 31 10:30 PM. Then, changes will post as Updates.

Author's Valuation

US$822.0% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$8

22.0% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.02%

Healthcare Services revenue growth rate

0.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.55%

Calculation

US$42.08m

Earnings '28

0.83x

PE Ratio '28

US$35.02m

Market Cap '28

US$35.02m

Market Cap '28

3.30m

No. shares '28

US$10.61

Share Price '28

US$10.61 Share Price '28

Discounted to 2025 @ 9.87% p.a.

US$8.00

Fair Value '25